157 related articles for article (PubMed ID: 26516615)
21. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.
Palace J; Newsom-Davis J; Lecky B
Neurology; 1998 Jun; 50(6):1778-83. PubMed ID: 9633727
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW
J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858
[TBL] [Abstract][Full Text] [Related]
23. Azathioprine in the treatment of myasthenia gravis.
Witte AS; Cornblath DR; Parry GJ; Lisak RP; Schatz NJ
Ann Neurol; 1984 Jun; 15(6):602-5. PubMed ID: 6742794
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus-associated hemophagocytic lymphohistiocytosis in a patient with myasthenia gravis treated with azathioprine.
Frederiksen JK; Ross CW
Blood; 2014 Apr; 123(15):2290. PubMed ID: 24895699
[No Abstract] [Full Text] [Related]
25. [A post-thymomectomy case of myasthenia gravis which developed nephrotic syndrome with membranous nephropathy during azathioprine administration].
Konishi T; Miki S; Yoshida A; Tei M
Rinsho Shinkeigaku; 1996 Jul; 36(7):864-8. PubMed ID: 8952354
[TBL] [Abstract][Full Text] [Related]
26. Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review.
Dillon P; Thomas N; Sharpless N; Collichio F
Med Oncol; 2010 Dec; 27(4):1127-32. PubMed ID: 19890737
[TBL] [Abstract][Full Text] [Related]
27. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients.
Mackenzie KA; Wells JE; Lynn KL; Simcock JW; Robinson BA; Roake JA; Currie MJ
Nephrol Dial Transplant; 2010 Jan; 25(1):300-6. PubMed ID: 19783601
[TBL] [Abstract][Full Text] [Related]
28. Portal hypertension secondary to azathioprine in myasthenia gravis.
Fonseca V; Havard CW
Postgrad Med J; 1988 Dec; 64(758):950-2. PubMed ID: 3256814
[TBL] [Abstract][Full Text] [Related]
29. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis?
Herrlinger U; Weller M; Dichgans J; Melms A
Ann Neurol; 2000 May; 47(5):682-3. PubMed ID: 10805346
[No Abstract] [Full Text] [Related]
30. The role of new immunosuppressive drugs in nonmelanoma skin cancer in renal transplant recipients.
Bernat-García J; Morales Suárez-Varela M; Vilata-Corell JJ; Marquina-Vila A; Pallardo L; Crespo J
Actas Dermosifiliogr; 2014 Dec; 105(10):940-6. PubMed ID: 25062648
[TBL] [Abstract][Full Text] [Related]
31. Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation.
Vos M; Plasmeijer EI; van Bemmel BC; van der Bij W; Klaver NS; Erasmus ME; de Bock GH; Verschuuren EAM; Rácz E
J Heart Lung Transplant; 2018 Jul; 37(7):853-859. PubMed ID: 29680587
[TBL] [Abstract][Full Text] [Related]
32. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study.
Tessari G; Naldi L; Boschiero L; Nacchia F; Fior F; Forni A; Rugiu C; Faggian G; Sassi F; Gotti E; Fiocchi R; Talamini G; Girolomoni G
Arch Dermatol; 2010 Mar; 146(3):294-9. PubMed ID: 20231501
[TBL] [Abstract][Full Text] [Related]
33. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
34. Nonmelanoma skin cancer after liver transplantation. Study of risk factors.
Herrero JI; España A; Quiroga J; Sangro B; Pardo F; Alvárez-Cienfuegos J; Prieto J
Liver Transpl; 2005 Sep; 11(9):1100-6. PubMed ID: 16123952
[TBL] [Abstract][Full Text] [Related]
35. A Review of Azathioprine-Associated Hepatotoxicity and Myelosuppression in Myasthenia Gravis.
Jack KL; Koopman WJ; Hulley D; Nicolle MW
J Clin Neuromuscul Dis; 2016 Sep; 18(1):12-20. PubMed ID: 27552384
[TBL] [Abstract][Full Text] [Related]
36. [Hypersensitivity to azathioprine can simulate an aggravation of myasthenia].
Chevrel G; Moreau T; Vial T; Payen C; Confavreux C
Therapie; 1998; 53(1):77-8. PubMed ID: 9773103
[No Abstract] [Full Text] [Related]
37. Safety of long-term combined immunosuppressive treatment in myasthenia gravis--analysis of adverse effects of 163 patients.
Rozsa C; Lovas G; Fornadi L; Szabo G; Komoly S
Eur J Neurol; 2006 Sep; 13(9):947-52. PubMed ID: 16930359
[TBL] [Abstract][Full Text] [Related]
38. Sweet syndrome as a manifestation of azathioprine hypersensitivity.
El-Azhary RA; Brunner KL; Gibson LE
Mayo Clin Proc; 2008 Sep; 83(9):1026-30. PubMed ID: 18775203
[TBL] [Abstract][Full Text] [Related]
39. Nonmelanoma skin cancer after renal transplantation: a single-center experience in 1736 transplantations.
Zavos G; Karidis NP; Tsourouflis G; Bokos J; Diles K; Sotirchos G; Theodoropoulou E; Kostakis A
Int J Dermatol; 2011 Dec; 50(12):1496-500. PubMed ID: 21790552
[TBL] [Abstract][Full Text] [Related]
40. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis.
Cosi V; Lombardi M; Erbetta A; Piccolo G
Acta Neurol (Napoli); 1993 Apr; 15(2):123-31. PubMed ID: 8328322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
